Department of Gastroenterology and Hepatology, Cleveland Clinic, Cleveland, OH 44195, USA.
Cleve Clin J Med. 2012 Mar;79(3):213-22. doi: 10.3949/ccjm.79a.11082.
Recent trials evaluated the safety and efficacy of two protease inhibitors, boceprevir (Victrelis) and telaprevir (Incivek), added to standard care with pegylated interferon and ribavirin, in patients with chronic hepatitis C virus (HCV) infection. These drugs open the door for triple therapy and other new therapies involving combinations of other direct-acting antiviral agents to become the new standard of care for this population.
最近的试验评估了两种蛋白酶抑制剂，博赛泼维（Victrelis）和替拉瑞韦（Incivek），联合聚乙二醇干扰素和利巴韦林标准治疗方案，用于慢性丙型肝炎病毒（HCV）感染患者。这些药物为三联疗法和其他涉及其他直接作用抗病毒药物组合的新疗法打开了大门，成为该人群的新标准治疗方法。
Zotero 插件